A recent study demonstrated that the RUNX1 allele dosage may determine the RUNX1 mutation-associated gene expression signature and identified a distinct RUNX1mut AML subgroup with significant association with FAB M0 morphology, trisomy 13, and ASXL1 mutations, whereas a chemogenomic approach revealed that AML samples bearing inactivating mutations of RUNX1 were particularly sensitive to nanomolar concentrations of glucocorticoids (110). Here, ASXL1 is linked to acute myeloid leukemia.